Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — you should not take two 2.5mg Mounjaro pens in place of one 5mg dose. Each Mounjaro KwikPen delivers four weekly injections at a fixed strength; splitting or doubling doses isn't how the medicine is designed to work, and doing so carries real safety risks. The licensed dosing schedule, which starts at 2.5mg once weekly and moves upward only under prescriber guidance, exists because the titration steps are built around how your body adapts to tirzepatide — not as a cost-saving workaround. If your 5mg pen is unavailable or you're wondering whether two lower-strength pens would add up to the same thing, the answer from clinical guidance is clear: they don't, and they shouldn't be combined. The NHS tirzepatide medicines page advises patients to follow their prescriber's instructions exactly and to contact their healthcare team if they have any concerns about their dose.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide's prescribing information (published on the Electronic Medicines Compendium and reviewed by the MHRA) is specific: one injection, once weekly, at the prescribed strength. The schedule begins at 2.5mg for the first four weeks as a tolerability phase. That starting pen isn't a half-measure waiting to be doubled; its job is to let your digestive system settle before the dose moves upward. After four weeks, the prescriber considers whether to increase to 5mg, then 7.5mg, and so on through the six licensed UK strengths up to 15mg, each step spaced roughly four weeks apart.
The reason the titration is staged this way is rooted in how the medicine works. Tirzepatide activates both GIP and GLP-1 receptors simultaneously, and any meaningful jump in dose can produce a sudden increase in nausea, vomiting, or diarrhoea. The steps exist precisely to reduce that risk. Compressing two 2.5mg doses into one week doesn't mimic a 5mg dose in any controlled sense, it delivers the same total quantity of drug in an uncontrolled pattern that the medicine was never trialled in. You can read more about how the 5mg Mounjaro pen fits into the overall treatment journey if you're approaching your first dose increase.
One misconception worth addressing: some people assume that because 2.5 + 2.5 = 5, two starter pens must be equivalent to the next strength. If you're uncertain whether that logic applies to your situation, it's worth reading through the full explanation of why taking two doses of 2.5mg Mounjaro isn't the same as stepping up, which covers the clinical reasoning in detail. The maths of milligrams doesn't translate into clinical equivalence when the timing, absorption and tolerability profile of each injection are fixed by design.
Administering two injections on the same day, or spreading them across a week as two separate doses, introduces the risk of tirzepatide overdose. The gastrointestinal consequences can be severe: rapid-onset nausea, prolonged vomiting, and diarrhoea that leads to dehydration. Dehydration on a GLP-1 or dual-agonist medicine can in turn affect kidney function, and that interaction is something the NHS medicines guidance for tirzepatide flags specifically.
Beyond the GI picture, an unintended dose spike may push blood sugar lower than expected in people who also take medicines that affect glucose, and can intensify any side effects that were already present at the lower dose. There is no clinical evidence that self-escalating the dose this way produces better weight-loss outcomes, the SURMOUNT-1 trial, which involved thousands of adults and was the basis for Mounjaro's UK weight-management licence, studied the structured titration protocol precisely because the researchers found it was the safest and most effective path to the higher maintenance doses.
If you've experienced side effects at your current dose and are wondering whether staying at 2.5mg a little longer might suit you better, that's a completely reasonable question, and one our prescribers hear regularly. The answer to it, though, lies in a clinical conversation, not in adjusting quantities independently. You can also explore how gastrointestinal side effects are managed at higher Mounjaro doses to understand what the clinical response looks like when the step-up does cause symptoms.
Mounjaro supply has been variable across the UK private market, and it's not unusual for patients to find their usual strength temporarily unavailable. If you've been prescribed 5mg but can only access 2.5mg pens, the right step is to contact your prescriber before making any change. Depending on your clinical picture, they may advise waiting, temporarily continuing on 2.5mg for one further week, or exploring availability through a different route.
What they will not advise is taking two 2.5mg injections to compensate. The guidance on how to use the 2.5mg pen correctly is unambiguous on this point: one injection per week, one pen per dose. If you're between prescriptions or have questions about stock, our support team is available seven days a week and can escalate to a prescriber the same day if needed.
For anyone researching Mounjaro more broadly (including what the full treatment journey looks like and what a private prescription actually costs) the Mounjaro treatment overview is a good starting point, and the Mounjaro cost page covers what private pricing typically includes so you know what to compare. If you're ready to speak to one of our prescribers about the right dose for you, you can start your free consultation at any point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.